When Regulatory Strategy Becomes a Commercial Advantage

By Christine Scheve, Vice President, Client Solutions

This spring’s EU MedTech Forum produced a rare kind of consensus. Across panels on diagnostics, software, evidence, and materials, the same theme kept emerging: 

The wall that once separated regulatory compliance from commercial success has come down, and the companies adapting fastest treat regulatory strategy like a commercial discipline rather than a downstream checkpoint. 

That shift carries more weight in 2026 than it did even a year ago. The EU is midway through a targeted revision of its medical device rules, the European Database on Medical Devices (EUDAMED) IT system is becoming mandatory, AI and software devices are raising the evidence bar, and payers are asking for proof of value earlier in development.  

Each pressure point is usually owned by a different team. The advantage belongs to manufacturers who connect them.

The forces reshaping EU MedTech in 2026

Christine Scheve, an RQM+ subject matter expert and VP of client solutions, who attended the forum, came back with a clear read of where the pressure is concentrating. Six forces are converging at once, and most of them touch more than one function inside a manufacturer:

• AI and software as a medical device are scaling fast
  • So are expectations for how that software is validated and monitored after launch
• MDR and IVDR continue to strain resources
  • The EU is advancing a revision meant to ease administrative burden and certification bottlenecks
• Commercialization timelines are tightening
  • There is closer scrutiny on execution risk and time to market
• Evidence generation is expanding into the post-market phase
  • Real-world data and post-market surveillance carry growing weight here
• EUDAMED is moving from voluntary to mandatory use
  • The first four modules are required starting in May 2026
• Materials and contamination risk are under closer review
  • This raises the stakes on biocompatibility evaluation early in design

None of these is new on its own. What changed is that they arrived together, and they reward the same kind of behavior: plan across functions early or absorb the cost of fixing gaps later.

Regulatory strategy has moved to the front of development

For years, regulatory work was something addressed after a design was largely fixed. That sequence no longer fits the market. When reimbursement, clinical evidence, and regulatory planning start at the same time, each one shapes the others in ways that protect the commercialization timeline.

Reimbursement is the clearest example. Payers and health technology assessment bodies want evidence of economic value before approval, not after it. A reimbursement strategy built alongside the clinical plan lets a single study serve both regulatory and payer needs, which costs much less than running separate evidence programs one after the other. The same logic drives market access consulting, where coverage decisions depend on data that have to be designed in from the start.

Regulatory strategy becomes the connective tissue. It keeps a medical device go-to-market strategy aligned with what each market will actually require, and it turns scattered functional plans into one coherent path from concept to adoption.

Materials and evidence risk arise earlier than teams expect

Two areas consistently catch programs off guard late in development, and both are easier to manage early:

• The first is materials risk. Under MDR and IVDR, extractables and leachables work and biocompatibility evaluation carry more weight than ever, and an unexpected result in a chemical characterization study can stall a submission. This is where investigative chemistry earns its keep. Moving a compound from unknown to tentatively identified is a distinct analytical step, and Jordi Labs, an RQM+ Company, is differentiated in exactly that kind of problem solving. From a tentatively identified structure, the Lumo™ platform uses molecular properties to estimate a compound’s analytical response and produce quantification with a documented accuracy range, and because that estimate draws on molecular properties, the precision of the starting structure matters less than it would in a traditional surrogate approach 
• The second is evidence. Post-market surveillance and clinical follow-up have ceased being paperwork exercises. Regulators and payers now expect a living evidence base, and an AI medical device adds another layer, since model performance must be monitored as data and populations change. Building that monitoring in before launch is far cheaper than retrofitting it under tight scrutiny

How integrated execution turns pressure into momentum

Recognizing the trend is easy. Operationalizing it is where most organizations stall. This is because integration across regulatory, clinical, lab, and market access functions usually means more vendors, more handoffs, and more coordination overhead. RQM+ built SMART Solutions to remove that friction. 

The model comes in two forms:

1. Integrated SMART Solutions gives small and midsize manufacturers unified orchestration across the full life cycle under one governance structure.  
2. Functional SMART Solutions embeds structured leadership inside a single vertical for larger enterprises that need depth in one area without losing alignment to the broader program. Both scale horizontally and vertically as a program grows, without adding headcount or new vendors. 

Integrated execution changes how a program runs day to day: 

• Risks across regulatory, lab, clinical, and market access become visible earlier, before they turn into rework or recalls 
• Evidence is planned once to satisfy regulatory and payer needs together, instead of twice 
• Governance runs on clear roles and review cadences, so decisions do not stall between functions 
• Capacity expands from a focused starting point as the program evolves, without restarting vendor relationships

The result is the outcome the forum kept pointing toward, which is that regulatory pressure stops acting like a brake on commercialization and starts working as part of the engine.

Building or scaling a device for the EU market in 2026?

Connect with RQM+ to pressure-test your regulatory, evidence, and market access strategy before the gaps that surface late turn into commercial setbacks. Let’s make your MedTech program happen. 

References

1. MedTech Europe. Revision proposal is first step towards fixing Europe’s complex Medical Devices & Diagnostics rules. 16 December 2025. https://www.medtecheurope.org/2025/12/16/revision-proposal-is-first-step-towards-fixing-europes-complex-medical-devices-diagnostics-rules/ 
2. European Commission. EUDAMED overview. https://health.ec.europa.eu/medical-devices-eudamed/overview_en 
3. MedTech Europe. EUDAMED reaches a major milestone: mandatory use of the first four modules begins. 4 June 2026. https://www.medtecheurope.org/2026/06/04/eudamed-reaches-a-major-milestone-mandatory-use-of-the-first-four-modules-begins/ 

Back to Resources